During the corresponding time, Quanterix Corporation recorded a revenue increase by 35.42 % year on year, sequentially revenue fell by -7.48 %. While revenue at the Quanterix Corporation's corporate clients
Quanterix's Comment on Sales, Marketing and Customers
The company sells proprietary instruments and related consumables globally to research laboratories, contract research organizations (CROs), academic institutions, and biopharmaceutical companies. It provides contract research services and clinical laboratory testing, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory in Bedford, Massachusetts. Its Simoa platforms detect protein biomarkers at ultra-low concentrations to support the development of novel therapies and diagnostics. The acquisition of Akoya Biosciences, Inc. expands its offerings in spatial biology solutions for tissue analysis and spatial phenotyping, serving discovery, translational and clinical research, and diagnostics. The acquisition of Emission, Inc. facilitates expansion into a multiplex segment targeting third-party original equipment manufacturer customers with dye-encapsulating magnetic beads and a mid-plex platform.
Unlocking New Frontiers in Precision Medicine: Quanterix Accelerator Laboratory Secures Prestigious New York State Permit In a groundbreaking development poised to revolutionize the field of biomarker research, Quanterix Corporation (NASDAQ: QTRX) today proudly announced that its Quanterix Accelerator Laboratory has been awarded a coveted clinical laboratory permit by the New York State Department of Health (NYSDOH). This pivotal achievement marks a significant milestone not only for Quanterix but for the entire scientific community dedicated to ultra-sensitive biomarker detection and precision medicine.The newly acquired permit, under the Clinical Chemistry category, affirms the Quanterix Accelerator Labora...
In a significant breakthrough for Alzheimer’s disease (AD) detection and diagnosis, Quanterix Corporation (NASDAQ: QTRX) has unveiled promising data at the recent Alzheimer’s Association International Conference (AAIC) that advocates for a novel multi-marker testing framework, positioning it as a more effective strategy compared to the traditional standalone plasma p-Tau 217 measurements. This advancement in biomarker detection introduces a profound shift in how scientists and clinicians can interpret and analyze the biomarkers associated with Alzheimer s, potentially changing the landscape of early diagnosis and intervention in this debilitating disease.Alzheimer’s disease, the most prevalent form of ...
Quanterix Corporation, a leading provider of ultra-sensitive research products and high-definition diagnostics, has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Simoa phospho-Tau 217 (p-Tau 217) blood test. This groundbreaking designation marks a significant achievement in the field of Alzheimer s Disease (AD) diagnostics, as it has the potential to revolutionize the detection and evaluation of this debilitating neurodegenerative disorder.The Importance of the Breakthrough Device DesignationThe FDA s Breakthrough Device designation is granted to products that demonstrate the potential to provide more effective treatment or diagnosis for life-threatening or...
Quanterix’s Comment on Sales, Marketing and Customers
The company sells proprietary instruments and related consumables globally to research laboratories, contract research organizations (CROs), academic institutions, and biopharmaceutical companies. It provides contract research services and clinical laboratory testing, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory in Bedford, Massachusetts. Its Simoa platforms detect protein biomarkers at ultra-low concentrations to support the development of novel therapies and diagnostics. The acquisition of Akoya Biosciences, Inc. expands its offerings in spatial biology solutions for tissue analysis and spatial phenotyping, serving discovery, translational and clinical research, and diagnostics. The acquisition of Emission, Inc. facilitates expansion into a multiplex segment targeting third-party original equipment manufacturer customers with dye-encapsulating magnetic beads and a mid-plex platform.
Sources:
Quanterix Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Quanterix Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Quanterix Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
148.78 %